

18 July 2023

**Physiomics plc**  
(“PYC” or the “Company”)

**Director Dealing**

The Company announces that Dr Christophe Chassagnole, Chief Scientific Officer of Physiomics, has transferred, for no consideration, 500,000 ordinary shares of 0.4p each in the Company held in certificated form ("Ordinary Shares") to his nominee account with Interactive Investor Services Limited. The Ordinary Shares remain beneficially owned by Dr Chassagnole.

Accordingly, Dr Chassagnole's total holding in the Company will remain unchanged at 1,102,723 Ordinary Shares, representing approximately 0.81 per cent. of the Company's issued share capital.

**Enquiries:**

**Physiomics plc**

Dr Jim Millen, CEO

+44 (0)1865 784 980

**Hybridan LLP (Broker)**

Claire Louise Noyce

+44 (0) 203 764 2341

**Strand Hanson Ltd (NOMAD)**

James Dance

James Bellman

+44 (0)20 7409 3494

The Company's LEI is 213800A71DSZ6ABMTQ91

**PDMR Notification Forms**

<b>1.</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>	
a)	Name	Christophe Chassagnole
<b>2.</b>	<b>Reason for the Notification</b>	
a)	Position/status	Executive Director, CSO
b)	Initial notification/amendment	Initial notification
<b>3.</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	Physiomics plc
b)	LEI	213800A71DSZ6ABMTQ91

<b>4.</b>	<b>Details of the transaction(s):section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted</b>					
a)	Description of the Financial instrument, type of instrument	Physiomics plc Ordinary Shares				
	Identification code	ISIN: GB00BDR6W943				
b)	Nature of the Transaction	Transfer of securities held in paper share certificates to nominee account Interactive Investor Services Nominees Limited.				
c)	Price(s) and volume(s)	Dr Christophe Chassagnole <table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>N/A</td> <td>500,000</td> </tr> </tbody> </table>	Price(s)	Volume(s)	N/A	500,000
Price(s)	Volume(s)					
N/A	500,000					
d)	Aggregated information - Aggregated volume - Price	500,000 N/A				
e)	Date of the transaction	14 July 2023				
f)	Place of the transaction	Off market transaction				

## Notes to Editor

### About Physiomics

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 100 projects, involving over 50 targets and 75 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.